These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36969835)

  • 21. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
    Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
    J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
    [No Abstract]   [Full Text] [Related]  

  • 24. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
    Gammie T; Lu CY; Babar ZU
    PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China.
    Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X
    BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A multicenter survey of the accessibility of essential medicines for children in China].
    Dai Y; Li ZP; Xu H; Zhu L; Zhu YQ; Cheng H; Chen ZB; Huang QZ; Lei L; Li RQ; Li G; Li Y; Liao M; Lu QH; Shi XP; Sun HJ; Shi TL; Wu XX; Wang ZS; Xu J; Zhao G; Zhang GY; Chen C
    Zhonghua Er Ke Za Zhi; 2020 Apr; 58(4):301-307. PubMed ID: 32234137
    [No Abstract]   [Full Text] [Related]  

  • 29. What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China.
    Chen C; Feng Z; Ding Y; Yan Z; Wang J; Wang R; Feng D
    Front Pharmacol; 2021; 12():734637. PubMed ID: 34630110
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of patient access to orphan drugs in Turkey.
    Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
    Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.
    Huang Y; Jiang Y; Zhang L; Mao W; van Boven JFM; Postma MJ; Chen W
    BMC Health Serv Res; 2018 Mar; 18(1):218. PubMed ID: 29587742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of universal medical insurance system on the accessibility of medical service supply and affordability of patients in China.
    Xiong X; Zhang Z; Ren J; Zhang J; Pan X; Zhang L; Gong S; Jin S
    PLoS One; 2018; 13(3):e0193273. PubMed ID: 29513712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accessibility of drugs for rare diseases in China: Policies and current situation.
    Yang Y; Kang Q; Hu J; Kong F; Tang M; He J; Jin C
    Intractable Rare Dis Res; 2019 May; 8(2):80-88. PubMed ID: 31218157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study on the accessibility and affordability of 50 drugs in Wuhan based on the WHO/HAI standardization method.
    Dong Z; Zhang S; Wu S; Xie X; Sun G; Yu X
    Front Public Health; 2023; 11():1108007. PubMed ID: 36778547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
    Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
    Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.